Section Editors : Carmen Jeronimo and Maria Berdasco
Associate Editors : Nita Ahuja, James Chim (haematological-based cancers only); Jim Davie, James Flanagan, Mario Fraga, Michéle Hoffmann, Bozena Kaminska (gliomas), Gwen Lomberk, Graham K Packham, Arpad Patai (colorectal/GI cancers), Qian Tao, Raul Urrutia, Keishi Yamashita
The development of genome-wide techniques has rapidly improved the comprehensive knowledge of epigenetic alterations in cancer. Currently, a vast number of genes and their associated molecular pathways that show epigenetic differences between normal and tumoral cells have been identified, emphasizing the crucial role of epigenetic factors in cancer etiology and progression. This section publishes original epigenetic research focused on the identification of epigenetic biomarkers associated with cancer diagnosis or tumor progression. Manuscripts on epigenetic biomarkers leading to a better definition of therapy response are also accepted (pharmacoepigenetics). Submissions on reports from human clinical trials providing insights on the clinical application of epigenetic biomarkers are welcomed.